Respiree
Houston, Texas, United States · Artificial Intelligence, Biotechnology, Health Care
Respiree™ is an AI/ML health tech company building state-of-the-art clinically-validated artificial intelligence (AI) for managing disease progression across healthcare’s care continuum. The 1Bio™ platform by Respiree™ uses data from the EHR and its proprietary US-patented and FDA-cleared sensors to longitudinal measure and track disease progression. Respiree™ is now available in U.S., Australia a
Key facts
- Headquarters
- Houston, Texas, United States
- Employees
- 26
- Industries
- Artificial Intelligence, Biotechnology, Health Care
- Status
- Private
- Website
- www.respiree.com
- Company page
Recent activity at Respiree
- : Respiree secures additional funding in a Series A extension led by We Venture Capital and ClavystBio to enhance its global commercial efforts.
- : Respiree secures $11.6M in Series A funding led by We Venture Capital and ClavystBio to expand its commercial team and U.S. presence.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Respiree funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2026 | Series A | Undisclosed |
| Jul 2025 | Series A | $11.6M |
Leadership
- Amit Rushi, Senior Vice President (SVP), Business Development & Strategy
- Devarshi, Head of Software Engineering
- Daniel Yap, Vice President of Operations
- Gurpreet Singh, Chief Executive Officer
Verified email and direct lines for Respiree’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Respiree in the news
- Respiree gets FDA nod to expand cardio-respiratory wearable to home use - MassDevice (Aug 06, 2025)
- Respiree Partners with Roche to Transform Patient Monitoring in APAC with Real-Time Bedside Solutions - BioPharma APAC (Sep 18, 2024)
- Respiree Secures Second FDA 510(k) Clearance, Expands Cardio-Respiratory Wearable to Home Use via 1Bio™ Connected Care Platform - BioSpace (Aug 05, 2025)
- Singapore OKs first AI alternative to inpatient EWS - MobiHealthNews (Dec 11, 2025)
- Respiree Extends Series A Syndicate with Addition of International Investors to Support Continued Global Growth - GlobeNewswire (Sep 21, 2026)
- Respiree Closes US$11.6M Series A Financing Round Led by We Venture Capital and ClavystBio - GlobeNewswire (Jul 23, 2025)
Companies similar to Respiree
- Ryght · Artificial Intelligence, Biotechnology, Health Care, Information Technology, Machine Learning
- Chai Discovery · Artificial Intelligence, Biotechnology, Health Care, Information Technology, Machine Learning
- OmicsBank · Artificial Intelligence, Biotechnology, Health Care, Information Technology, Machine Learning
- UCANACT · Artificial Intelligence, Biotechnology, Health Care, Information Technology, Machine Learning
- AKASA · Artificial Intelligence, Biotechnology, Health Care, Information Technology, Machine Learning
About Respiree: questions and answers
What does Respiree do?
Respiree™ is an AI/ML health tech company building state-of-the-art clinically-validated artificial intelligence (AI) for managing disease progression across healthcare’s care continuum. The 1Bio™ platform by Respiree™ uses data from the EHR and its proprietary US-patented and FDA-cleared sensors to longitudinal measure and track disease progression. Respiree™ is now available in U.S., Australia a
Where is Respiree headquartered?
Respiree is headquartered in Houston, Texas, United States.
How many employees does Respiree have?
Respiree has about 26 employees.
Has Respiree raised funding?
Yes. Fundz has recorded 2 funding events for Respiree. The most recent, Series A of Undisclosed, was in Sep 2026.
Who leads Respiree?
Amit Rushi is a Senior Vice President (SVP), Business Development & Strategy at Respiree.
What is the latest news on Respiree?
On Sep 22, 2026, Respiree secures additional funding in a Series A extension led by We Venture Capital and ClavystBio to enhance its global commercial efforts.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy